Uric acid-to-albumin ratio × monocyte-to-lymphocyte ratio is a novel biomarker for predicting all-cause mortality and cardiovascular mortality in patients with ST-segment elevation myocardial infarction

尿酸/白蛋白比值×单核细胞/淋巴细胞比值是预测ST段抬高型心肌梗死患者全因死亡率和心血管死亡率的新型生物标志物。

阅读:1

Abstract

BACKGROUND: Uric acid-to-albumin ratio (UAR) and monocyte-to-lymphocyte ratio (MLR) predict adverse outcomes in cardiovascular disease (CVD). We aim to explore the predictive value of UAR combined with MLR for all-cause and cardiovascular mortality in patients with ST-segment elevation myocardial infarction (STEMI). METHODS: This retrospective cohort study included 1045 patients with STEMI who had undergone emergency percutaneous coronary intervention (PCI) (2018-2023). Uric acid-to-albumin ratio × monocyte-to-lymphocyte ratio (UAML) was defined as the product of UAR and MLR. Mortality prediction was evaluated via Kaplan-Meier, Cox regression, and time-dependent receiver operating characteristic (ROC) analyses. RESULTS: Stratifying 1045 patients with STEMI by median UAML (3.35) revealed significantly higher cumulative all-cause mortality (log-rank χ2 =41.114, P < 0.001) and cardiovascular mortality ( χ2 = 32.153, P < 0.001) in the high-UAML (≥3.35) vs. low-UAML (<3.35) group. Multivariate Cox analysis confirmed UAML as an independent predictor of all-cause mortality [hazard ratio (HR) = 2.217, 95% confidence interval (CI): 1.399-3.514; P < 0.001] and cardiovascular mortality (HR = 2.160, 95% CI: 1.267-3.618; P = 0.005). Time-dependent ROC demonstrated superior predictive discrimination for UAML over individual components in both all-cause mortality [area under the ROC curve (AUC) = 0.704 vs. UAR = 0.686/MLR = 0.627] and cardiovascular mortality (AUC = 0.700 vs. 0.690/0.615). CONCLUSION: UAML may serve as a strong prognostic factor for all-cause and cardiovascular mortality in patients with STEMI who undergo emergency PCI, and UAML has a stronger predictive value than UAR or MLR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。